VYNE Therapeutics Files 8-K
Ticker: VYNE · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1566044
| Field | Detail |
|---|---|
| Company | Vyne Therapeutics Inc. (VYNE) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
TL;DR
VYNE filed a routine 8-K, no major news.
AI Summary
VYNE Therapeutics Inc. filed an 8-K on September 12, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial details or new material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates standard corporate reporting by VYNE Therapeutics Inc. to the SEC, without disclosing new material events or financial updates.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no new material information, indicating no immediate change in risk.
Key Players & Entities
- VYNE Therapeutics Inc. (company) — Registrant
- September 12, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-38356 (identifier) — Commission File Number
- 45-3757789 (identifier) — IRS Employer Identification Number
- Menlo Therapeutics Inc. (company) — Former Company Name
- Tigercat Pharma, Inc. (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for VYNE Therapeutics Inc.?
The primary purpose is to report "Other Events" and "Financial Statements and Exhibits" as of September 12, 2024.
When was this 8-K report filed?
This 8-K report was filed on September 12, 2024.
What is the state of incorporation for VYNE Therapeutics Inc.?
VYNE Therapeutics Inc. is incorporated in Delaware.
What are some of the former names of VYNE Therapeutics Inc. mentioned in the filing?
Former names include Menlo Therapeutics Inc. and Tigercat Pharma, Inc.
Does this filing disclose any specific new financial results or material business developments?
The provided excerpt of the 8-K filing does not disclose specific new financial results or material business developments; it indicates standard reporting items.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-09-12 08:01:12
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value VYNE The Nasdaq Stock Mar
Filing Documents
- tm2423851d1_8k.htm (8-K) — 25KB
- tm2423851d1_ex99-1.htm (EX-99.1) — 17KB
- tm2423851d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-24-099121.txt ( ) — 225KB
- vyne-20240912.xsd (EX-101.SCH) — 3KB
- vyne-20240912_lab.xml (EX-101.LAB) — 33KB
- vyne-20240912_pre.xml (EX-101.PRE) — 22KB
- tm2423851d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 12, 2024, VYNE Therapeutics Inc. issued a press release entitled "VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated September 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VYNE THERAPEUTICS INC . Date: September 12, 2024 By: /s/ Mutya Harsch Mutya Harsch Chief Legal Officer and General Counsel